An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public trust.
CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...
You may have seen ads for a new, lower-dose Moderna COVID vaccine marketed to "the senior class" - adults 65 and older. The new vaccine, which goes by mRNA-1283 or mNexspike, was approved by the U.S.
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / ...
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results